Identification of potential therapeutic targets for idiopathic pulmonary fibrosis: an integrated multiomics analysis - Takeaways - MDSpire

Identification of potential therapeutic targets for idiopathic pulmonary fibrosis: an integrated multiomics analysis

  • By

  • Xingxuan Chen

  • Shibin Chen

  • Shuai Zhao

  • Yupeng Li

  • Jingkun Chang

  • Si Shi

  • Dandan Xu

  • Lijuan Li

  • Hong Chen

  • June 5, 2026

  • 0 min

Share

  • 1

    Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a median survival of 2 to 3 years post-diagnosis.

  • 2

    Current antifibrotic treatments can slow IPF progression but do not reverse established fibrosis, necessitating new therapeutic targets.

  • 3

    The study identified twelve proteins associated with IPF risk, including eight pro-fibrotic mediators and four protective factors.

  • 4

    Four candidate proteins were prioritized: SCARF2 as a protective factor and FN1, PPID, and CDON as pro-fibrotic factors.

  • 5

    The research utilized multi-omics integration and experimental validation to propose novel therapeutic targets for IPF.

Original Source(s)

Identification of potential therapeutic targets for idiopathic pulmonary fibrosis: an integrated multiomics analysis

  • by Xingxuan Chen, Shibin Chen, Shuai Zhao, Yupeng Li, Jingkun Chang, Si Shi, Dandan Xu, Lijuan Li, Hong Chen

  • June 5, 2026

Related Content

Forecasting the Impacts of Artificial Intelligence Assistance in Virtual Consultations for Chronic Obstructive Pulmonary Disease: Exploratory Futures Wheel Study

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging